FI901344A0 - Monoklonala antikroppar reaktiva med tnf. - Google Patents

Monoklonala antikroppar reaktiva med tnf.

Info

Publication number
FI901344A0
FI901344A0 FI901344A FI901344A FI901344A0 FI 901344 A0 FI901344 A0 FI 901344A0 FI 901344 A FI901344 A FI 901344A FI 901344 A FI901344 A FI 901344A FI 901344 A0 FI901344 A0 FI 901344A0
Authority
FI
Finland
Prior art keywords
reaktiva
tnf
med
antikroppar
monoclonal
Prior art date
Application number
FI901344A
Other languages
English (en)
Other versions
FI101937B1 (fi
FI101937B (fi
Inventor
George Kuo
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of FI901344A0 publication Critical patent/FI901344A0/fi
Priority to FI954230A priority Critical patent/FI102115B1/fi
Application granted granted Critical
Publication of FI101937B1 publication Critical patent/FI101937B1/fi
Publication of FI101937B publication Critical patent/FI101937B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
FI901344A 1988-07-18 1990-03-16 Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmi sen cachectiinin kanssa FI101937B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI954230A FI102115B1 (fi) 1988-07-18 1995-09-08 Diagnostiikassa käytettävä monoklonaalinen vasta-ainekoostumus ja sitä sisältävä testipakkaus

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22020688A 1988-07-18 1988-07-18
US22020688 1988-07-18
PCT/US1989/003025 WO1990000902A1 (en) 1988-07-18 1989-07-12 Monoclonal antibodies reactive with cachectin
US8903025 1989-07-12

Publications (3)

Publication Number Publication Date
FI901344A0 true FI901344A0 (fi) 1990-03-16
FI101937B1 FI101937B1 (fi) 1998-09-30
FI101937B FI101937B (fi) 1998-09-30

Family

ID=22822529

Family Applications (1)

Application Number Title Priority Date Filing Date
FI901344A FI101937B (fi) 1988-07-18 1990-03-16 Menetelmä monoklonaalisen vasta-aineen tuottamiseksi, joka reagoi ihmi sen cachectiinin kanssa

Country Status (16)

Country Link
US (1) US5658803A (fi)
EP (1) EP0351789B1 (fi)
JP (1) JP2638652B2 (fi)
AT (1) ATE173766T1 (fi)
AU (1) AU626572B2 (fi)
CA (1) CA1340018C (fi)
DE (1) DE68928857T2 (fi)
DK (1) DK69890A (fi)
ES (1) ES2124209T3 (fi)
FI (1) FI101937B (fi)
IL (1) IL90990A (fi)
NO (1) NO179615C (fi)
NZ (1) NZ229922A (fi)
PT (1) PT91201B (fi)
WO (1) WO1990000902A1 (fi)
ZA (1) ZA895372B (fi)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
DE10399036I1 (de) * 1989-08-07 2004-04-01 Peptide Technology Ltd Bindeligande für Tumornekrosisfaktor.
US6498237B2 (en) 1989-08-07 2002-12-24 Peptech Limited Tumor necrosis factor antibodies
GB8918232D0 (en) * 1989-08-10 1989-09-20 Opal Stephen M Pharmaceutical product for the treatment of septic shock
DE69033457T2 (de) * 1989-08-16 2000-09-14 Chiron Corp Prohormonspaltungsplatzblockierungsantikörper
DE4037604A1 (de) * 1990-04-25 1991-10-31 Bayer Ag Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen
ATE197646T1 (de) * 1990-08-06 2000-12-15 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
JPH06505969A (ja) * 1991-01-11 1994-07-07 レプリジェン　コーポレーション 炎症性損傷防止方法
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE07006112T1 (de) * 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP0525570A3 (en) * 1991-07-31 1993-10-06 Miles Inc. Anti-idiotypic antibodies that mimic tnf
ES2121907T3 (es) * 1992-08-28 1998-12-16 Bayer Ag Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas.
ES2138662T3 (es) * 1993-06-03 2000-01-16 Therapeutic Antibodies Inc Produccion de fragmentos de anticuerpos.
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
AU3632595A (en) * 1994-09-15 1996-03-29 Verigen, Inc Porcine antibodies to tnf-alpha(alpha)
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
DE19746868A1 (de) * 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US20050045635A1 (en) * 2003-09-03 2005-03-03 Jane Dong Containers for storing articles
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
CN101500607B (zh) 2005-05-16 2013-11-27 阿布维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CA2632519A1 (en) * 2005-12-06 2007-07-05 Amgen Inc. Polishing steps used in multi-step protein purification processes
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US9624295B2 (en) 2006-04-10 2017-04-18 Abbvie Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
AU2014215639B2 (en) 2013-01-25 2017-03-23 Thymon, Llc Compositions for selective reduction of circulating bioactive soluble TNF and methods for treating TNF-mediated disease
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603106A (en) * 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4870163A (en) * 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
JPS63501724A (ja) * 1985-12-05 1988-07-14 バイオジェン インコーポレイテッド 腫瘍壊死因子及び抗生物質及び腫瘍処理方法の組合せ
US4834976A (en) * 1986-07-03 1989-05-30 Genetic Systems Corporation Monoclonal antibodies to pseudomonas aeruginosa flagella
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung

Also Published As

Publication number Publication date
NO179615B (no) 1996-08-05
PT91201B (pt) 1996-12-31
AU3970389A (en) 1990-02-19
DE68928857D1 (de) 1999-01-07
ATE173766T1 (de) 1998-12-15
FI101937B1 (fi) 1998-09-30
NZ229922A (en) 1992-04-28
ES2124209T3 (es) 1999-02-01
NO901247L (no) 1990-03-16
ZA895372B (en) 1990-04-25
FI101937B (fi) 1998-09-30
DK69890D0 (da) 1990-03-16
NO901247D0 (no) 1990-03-16
AU626572B2 (en) 1992-08-06
EP0351789B1 (en) 1998-11-25
CA1340018C (en) 1998-09-01
JPH03501330A (ja) 1991-03-28
DE68928857T2 (de) 1999-08-05
DK69890A (da) 1990-05-15
PT91201A (pt) 1990-02-08
IL90990A0 (en) 1990-02-09
EP0351789A2 (en) 1990-01-24
IL90990A (en) 1994-10-21
EP0351789A3 (en) 1990-08-01
US5658803A (en) 1997-08-19
JP2638652B2 (ja) 1997-08-06
NO179615C (no) 1996-11-13
WO1990000902A1 (en) 1990-02-08

Similar Documents

Publication Publication Date Title
FI901344A0 (fi) Monoklonala antikroppar reaktiva med tnf.
EP0260610A3 (en) Monoclonal antibodies against human tumour necrotic factor (tnf), and their use
AU4472793A (en) Methods for diagnosis and therapy using defined regions of the T cell antigen receptor
ZA887987B (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
DE68929279T2 (de) Lederbehandlung mit ausgewählten amphiphilen Copolymeren
DE68913789T2 (de) Aufladevorrichtung und Bilderzeugungsgerät mit dieser.
GR3033630T3 (en) Gene expression elements and the production of chimeric mouse-human antibodies.
DE3481035D1 (de) Ibuprofen, flurbiprofen und deren therapeutische verwendung.
EP0199141A3 (en) Monoclonal antibodies to human gastrointestinal cancer
DE3889062T2 (de) Monoklonaler Antikörper gegen humanen BCDF.
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
CA2192079A1 (en) Human Monoclonal Antibodies Specific to Cell Cycle Independent Glioma Surface Antigen
AU628288B2 (en) Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins
IL71017A0 (en) Hybrid cell lines,monoclonal antibodies prepared thereby and their use in the purification,diagnosis and detection of human interferon
EP0339163A3 (en) Monoclonal antibodies specific for hiv and hybridomas for their production
PL325667A1 (en) Antibodies effective against fas
EP0505749A3 (en) Monoclonal antibodies directed to activated endothelial cells and their therapeutic and diagnostic use
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
ATE99332T1 (de) Monoklonale antikoerper gegen menschliche interleukin-4 und die sie erzeugenden hybridomen.
IT8215234V0 (it) Schermo riflettente per l abbronzatura solare completa ed omogenea del corpo
ZW4783A1 (en) Antibodies and antigens useful in the diagnosis and treatment of cancer
ZA831050B (en) Antibodies and antigens useful in the diagnosis and treatment of cancer
NO884613L (no) Human interleukin-3- og muteiner derav.
DK451177A (da) Fyldelegeme af plast isaer til biologiske spildevandsrensningsanlaeg og fremgangsmaade til fremstilling af plastlegemet
FI880188A0 (fi) Wobbler med flere funktioner.

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: CHIRON CORPORATION